<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03010423</url>
  </required_header>
  <id_info>
    <org_study_id>EMR200505_506</org_study_id>
    <nct_id>NCT03010423</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Oral Nicorandil on Improving Microvascular Function in Female Non-obstructive Coronary Artery Disease (CAD) Subjects</brief_title>
  <acronym>SPET</acronym>
  <official_title>An Interventional, Pilot Study to Evaluate the Efficacy of Oral Nicorandil on Improving Microvascular Function in Female Non-obstructive CAD Patients (SPET Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono Co., Ltd., China</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a single-center, interventional, pilot study to evaluate the improvement of
      microvascular function by positron emission tomography (PET) after twelve-week treatment of
      oral nicorandil in female non-obstructive CAD subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2016</start_date>
  <completion_date type="Anticipated">June 20, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Myocardial Blood Flow Reserve (MFR) by stress PET at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Myocardial Blood Flow (MBF) by rest PET at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in MBF by stress PET at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Ejection Fraction at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Left Ventricular End-Systolic Dimension (LVESD) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in left ventricular wall thickness at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in cardiac diastolic function: early [E] to late [A] ventricular filling velocities (E/A) ratio at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Seattle Angina Questionnaire(SAQ) score at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non-obstructive Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Nicorandil treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicorandil</intervention_name>
    <description>Subjects will be administered nicorandil 5 milligram (mg) tablet, three times a day for 12 weeks</description>
    <arm_group_label>Nicorandil treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard treatment</intervention_name>
    <description>Subjects will continue to take the standard treatment, which is stabilized at least one month before screening period without any other newly added drugs. The standard treatment will include but is not limited to aspirin/clopidogrel, calcium channel blockers (CCB), angiotensin-converting-enzyme inhibitor (ACEI)/Angiotensin receptor blockers (ARBs), beta-blockers, statins if condition permits.</description>
    <arm_group_label>Nicorandil treatment group</arm_group_label>
    <arm_group_label>Standard treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Female

          -  Subjects aged 18-70 years

          -  Subjects with typical stable angina but without coronary obstruction (defined as
             coronary occlusion less than (&lt;) 20%) by invasive coronary angiography or coronary
             computed tomography angiography (CTA) in recent three months

          -  ST-segment with horizontal or downward sloping down more than or equal to (&gt;=) 0.1
             millivolt (mV) in electrocardiogram (ECG) during exercise stress test or when angina
             attacks; or positive results by adenosine stress myocardial perfusion tomographic
             imaging in recent three months

          -  All other long acting cardiovascular disease medicines, including but not limited to
             aspirin/clopidogrel, CCB, ACEI/ARB, beta-blockers, statins, ivabradine, trimetazidine,
             et al, should be stable taken for at least one month before screening period

          -  For Subjects who met these five criteria above, MFR will be tested by stress PET.
             Subjects whose MFR &lt;2.5 could be included in the study

        Exclusion criteria:

          -  Severe or uncontrolled hypertension (resting Systolic blood pressure [SBP] &gt;=160
             millimeter of mercury (mmHg), or resting Diastolic blood pressure [DBP] &gt;=100mmHg at
             screening period)

          -  Subjects with shock (including cardiogenic shock), or hypovolemia

          -  Severe hypotension (resting SBP&lt;90mmHgï¼Œor resting DBP&lt;60mmHg)

          -  Significant valvular heart disease, congenital heart disease or cardiomyopathy

          -  Congestive heart failure(New York Heart Association [NYHA] III-IV), echocardiographic
             ejection fraction&lt;45%

          -  Acute pulmonary edema;

          -  Hepatic or renal dysfunction, defined as:

               -  Serum Alanine Aminotransferase (ALT) &gt; triple of the normal value upper limit;

               -  Serum Aspartate Aminotransferase (AST) &gt; triple of the normal value upper limit

               -  Serum creatinine &gt; twice of the normal value upper limit

          -  Glaucoma

          -  Active peptic ulcer or active skin ulcer

          -  Taking glyburide, phosphodiesterase type 5 (PDE-5) inhibitor, soluble guanylate
             cyclase stimulator(s)

          -  Known to be hypersensitivity to nicorandil, nitrates, niacin, or any of the excipient

          -  With contraindication to complete stress PET test

          -  No legal ability and legal ability is limited

          -  Subjects unlikely to cooperate in the study or with inability or unwillingness to give
             informed consent

          -  Child-bearing period women without effective contraceptive measures, pregnancy and
             lactation

          -  Participation in another clinical trial within the past 30 days

          -  Other significant disease that in the Investigator's opinion would exclude the subject
             from the trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Serono Co., Ltd., China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Merck KGaA Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@merckgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking union medical college hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 6151 72 5200</phone>
      <email>service@merckgroup.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2017</study_first_submitted>
  <study_first_submitted_qc>January 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2017</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-obstructive coronary artery disease</keyword>
  <keyword>Nicorandil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicorandil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

